Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.
Galderma Group (SWX:GALD) has been drawing attention after recent share price swings, with a positive 1 day return standing in contrast to weaker performance over the past week, month, and past 3 months.
See our latest analysis for Galderma Group.
The latest 1 day share price return of 0.70% to CHF143.9 comes after weaker recent momentum. The 30 day share price return shows an 11.23% decline, which contrasts with a 1 year total shareholder return of 30.21%. This suggests earlier optimism has cooled as investors reassess growth prospects and risks.
If Galderma’s recent moves have caught your eye, it could be a moment to widen your watchlist and scan other healthcare stocks that fit your criteria.
With a 52% estimated intrinsic discount and a 15% gap to analyst targets, Galderma looks inexpensive on some measures. However, recent share price weakness raises the question: is this a genuine opening, or is future growth already priced in?
Galderma Group’s most followed narrative points to a fair value of CHF159.55 per share, above the last close at CHF143.90, which naturally draws attention.
The ongoing investment and success in R&D and partnerships (e.g., with L’Oréal for non-invasive skin imaging and expanded nemolizumab indications) position Galderma to capitalize on the growing health consciousness and demand for novel skin health solutions, which should support future revenue and earnings growth as innovative products reach the market.
Curious what kind of revenue path and margin lift need to play out to back that CHF159.55 figure? The narrative leans on punchy earnings expansion, higher quality mix, and a future profit multiple that assumes strong execution. Want to see exactly which financial levers carry the most weight in that story?
Result: Fair Value of CHF159.55 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, there is still real execution risk here, ranging from softer filler demand and price competition to heavy reliance on Nemluvio and Relfydess actually meeting expectations.
Find out about the key risks to this Galderma Group narrative.
While our model suggests Galderma trades at a 52.5% discount to fair value, the market is paying a very full P/E of 117.2x. That is far above the European pharma average of 26.6x, the peer average of 61.1x, and even the 39.2x fair ratio our work points to. For you, that gap is really a question of how much optimism you are comfortable paying for.
See what the numbers say about this price — find out in our valuation breakdown.
SWX:GALD P/E Ratio as at Jan 2026
If parts of this story do not quite match your view, or you prefer to crunch the numbers yourself, you can shape a custom thesis in just a few minutes with Do it your way.
A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Galderma Group.
If Galderma is on your radar, do not stop there. The Screener lets you quickly spot fresh ideas that fit your style before others move first.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include GALD.SW.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com